Besufetamig

倍斯妥米单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameBesufetamig

Drug Alias NameONO-4685

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 inhibitorsProgrammed cell death protein 1 blockers

TargetsProgrammed cell death protein 1T cell surface glycoprotein CD3

Therapy Area/IndicationsPlaque psoriasisLymphoma, T-CellLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRomaniaUnited KingdomMoldova, Republic of +[4]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMerus Nv

China Registration ClassN/A

Develop Information

Active CompaniesOno Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsPlaque psoriasisLymphoma, T-CellLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A